Biotech

All Articles

Pfizer takes $230M hit after axing failed DMD gene therapy

.Pfizer's stage 3 Duchenne muscular dystrophy (DMD) gene treatment failing has actually gone a $230 ...

AC Immune sees 'site' potential in Alzheimer's medication information

.After more than twenty years of work on neurodegenerative diseases, Swiss biotech a/c Immune system...

GSK goes down ph. 2 HPV vaccination over shortage of best-in-class prospective

.GSK has actually junked a phase 2 individual papillomavirus (HPV) vaccination from its pipe after m...

OS Treatments refiles $6M IPO to fund HER2 medication, preclinical ADCs

.OS Therapies will certainly specify on the NYSE American stock substitution today through a $6.4 mi...

ALX's fizzling CD47 response fee sends inventory spiraling down

.ALX Oncology's period 2 gastric cancer cells feedback rate has deteriorated. After observing its CD...

Ionis centers eye disease coming from aim ats of Roche-partnered prospect after records dissatisfy

.Another of Ionis Pharmaceuticals' crucial midphase readouts has actually disappointed assumptions, ...

Biogen's CEO pointed out no risky handle 2023. He's ready to be bold

.While Biogen's pharma peers are actually looking for late-stage possessions with little bit of thre...

Instil refills pipe in $2B biobucks handle ImmunOnco

.Instil Biography has actually been actually a biotech trying to find a pipeline after it ditched it...

Biogen walks away from Denali Alzheimer's collab

.Biogen has actually returned legal rights to a very early Alzheimer's disease plan to Denali Rehabs...

Takeda taps brand new mind of US oncology business-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our roundup of significant leadership hirings, firings ...